Company Overview and News

 
Canadian General Investments, Limited Declares Dividend on Series 4 Preference Shares

2018-10-17 globenewswire
TORONTO, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Canadian General Investments, Limited (TSX:CGI) (TSX:CGI.PR.D) (LSE:CGI) has declared a quarterly dividend on its Series 4 preference shares.
CGI CGI CGRIF

 
Canadian General Investments: Investment Update - Unaudited

2018-09-06 globenewswire
TORONTO, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Canadian General Investments, Limited (CGI) (TSX:CGI) (TSX:CGI.PR.D) (LSE:CGI) reports on an unaudited basis that its net asset value per share (NAV) at August 31, 2018 was $37.20, resulting in year-to-date and 12-month NAV returns, with dividends reinvested, of 14.1% and 29.2%, respectively. These compare with the 2.3% and 10.1% returns of the benchmark S&P/TSX Composite Index on a total return basis for the same periods.
CGI TXCX CGI CGRIF

 
Canadian General Investments: Investment Update - Unaudited

2018-08-03 globenewswire
TORONTO, Canada, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Canadian General Investments, Limited (CGI) (TSX:CGI) (TSX:CGI.PR.D) (LSE:CGI) reports on an unaudited basis that its net asset value per share (NAV) at July 31, 2018 was $35.72, resulting in year-to-date and 12-month NAV returns, with dividends reinvested, of 9.0% and 24.7%, respectively. These compare with the 3.1% and 11.7% returns of the benchmark S&P/TSX Composite Index on a total return basis for the same periods.
CGI TXCX CGI CGRIF

 
Canadian General Investments, Limited Files 2018 Interim Report

2018-08-03 globenewswire
TORONTO, Canada, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Canadian General Investments, Limited (the Company) (TSX:CGI) (TSX:CGI.PR.D) (LSE:CGI), announces that it has submitted its 2018 Interim Report, which includes the Management Report of Fund Performance and unaudited Financial Statements, to applicable Canadian securities regulators and to the National Storage Mechanism (http://www.morningstar.co.uk/uk/NSM).
CGI CGI CGRIF

 
Canadian General Investments, Limited Declares Dividend on Common Shares

2018-07-18 globenewswire
TORONTO, Canada, July 18, 2018 (GLOBE NEWSWIRE) -- Canadian General Investments, Limited (“CGI” or “the Company”) (TSX:CGI) (TSX:CGI.PR.D) (LSE:CGI) has declared a quarterly dividend of $0.19 per share payable on September 15, 2018 to common shareholders of record at the close of business on August 31, 2018 (“the Dividend”). This dividend is designated as an "eligible dividend” for purposes of the Income Tax Act (Canada).
CGI CGI CGRIF

 
Canadian General Investments, Limited Declares Dividend on Series 4 Preference Shares

2018-07-18 globenewswire
TORONTO, Canada, July 18, 2018 (GLOBE NEWSWIRE) -- Canadian General Investments, Limited (TSX:CGI) (TSX:CGI.PR.D) (LSE:CGI) has declared a quarterly dividend on its Series 4 preference shares.
CGI CGI CGRIF

 
Canadian General Investments: Investment Update - Unaudited

2018-07-05 globenewswire
TORONTO, July 05, 2018 (GLOBE NEWSWIRE) -- Canadian General Investments, Limited (CGI) (TSX:CGI) (TSX:CGI.PR.D) (LSE:CGI) reports on an unaudited basis that its net asset value per share (NAV) at June 30, 2018 was $35.73, resulting in year-to-date and 12-month NAV returns, with dividends reinvested, of 9.0% and 26.6%, respectively. These compare with the 1.9% and 10.4% returns of the benchmark S&P/TSX Composite Index on a total return basis for the same periods.
CGI TXCX CGI CGRIF

 
Canadian General Investments: Investment Update - Unaudited

2018-05-03 globenewswire
TORONTO, May 03, 2018 (GLOBE NEWSWIRE) -- Canadian General Investments, Limited (CGI) (TSX:CGI) (TSX:CGI.PR.D) (LSE:CGI) reports on an unaudited basis that its net asset value per share (NAV) at April 30, 2018 was $33.58, resulting in year-to-date and 12-month NAV returns, with dividends reinvested, of 1.9% and 17.5%, respectively. These compare with the -2.8% and 3.1% returns of the benchmark S&P/TSX Composite Index on a total return basis for the same periods.
CGI TXCX CGI CGRIF

 
Canadian General Investments: Report of Voting Results

2018-04-18 globenewswire
TORONTO, April 18, 2018 (GLOBE NEWSWIRE) -- Canadian General Investments, Limited (“CGI” or “the Company”) (TSX:CGI) (TSX:CGI.PR.D) (LSE:CGI) - This report is filed under section 16.3 of National Instrument 81-106 Investment Fund Continuous Disclosure in respect of the annual general meeting of shareholders of the Corporation held on April 18, 2018 (the “Meeting”).
CGI CGI CGRIF

 
Canadian General Investments, Limited Declares Dividend on Series 4 Preference Shares

2018-04-18 globenewswire
TORONTO, CANADA, April 18, 2018 (GLOBE NEWSWIRE) -- Canadian General Investments, Limited (TSX:CGI.PR.D) has declared a quarterly dividend on its Series 4 preference shares.
CGI CGI CGRIF

 
Canadian General Investments, Limited Declares Dividend on Common Shares

2018-04-18 globenewswire
TORONTO, CANADA, April 18, 2018 (GLOBE NEWSWIRE) -- Canadian General Investments, Limited (“CGI” or “the Company”) (TSX:CGI) (TSX:CGI.PR.D) (LSE:CGI) has declared a quarterly dividend of $0.19 per share payable on June 15, 2018 to common shareholders of record at the close of business on May 31, 2018 (“the Dividend”). This dividend is designated as an "eligible dividend” for purposes of the Income Tax Act (Canada).
CGI CGI CGRIF

 
Canadian General Investments: Investment Update - Unaudited

2018-04-04 globenewswire
TORONTO, CANADA, April 04, 2018 (GLOBE NEWSWIRE) -- Canadian General Investments, Limited (CGI) (TSX:CGI) (TSX:CGI.PR.D) (LSE:CGI) reports on an unaudited basis that its net asset value per share (NAV) at March 31, 2018 was $32.83, resulting in year-to-date and 12-month NAV returns, with dividends reinvested, of -0.4% and 16.6%, respectively. These compare with the -4.5% and 1.7% returns of the benchmark S&P/TSX Composite Index on a total return basis for the same periods.
CGI TXCX CGI CGRIF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TSX:CGI / CDN General Inv on message board site Silicon Investor.

CGI Group (GIB.A) - CGI Group (GIB.A) - CGI Group (GIB.A) - ECGI: Envoy Communications ECGI: Envoy Communications ECGI: Envoy Communications
BCGI = Boston Communications Group (Co turned profitable!) BCGI = Boston Communications Group (Co turned profitable!) BCGI = Boston Communications Group (Co turned profitable!) The Classica Group (TCGI on NASDAQ) The Classica Group (TCGI on NASDAQ) The Classica Group (TCGI on NASDAQ)
CCGI: ComTech Consolidated CCGI: ComTech Consolidated CCGI: ComTech Consolidated ICGI. Icommerce Group.. Internet holding company ICGI. Icommerce Group.. Internet holding company ICGI. Icommerce Group.. Internet holding company
C.G.I. Holding Corporation (OTC.BB: CGIC) C.G.I. Holding Corporation (OTC.BB: CGIC) C.G.I. Holding Corporation (OTC.BB: CGIC) RCGI - Renal Care Group Inc RCGI - Renal Care Group Inc RCGI - Renal Care Group Inc
Carnegie Group CGIX (READY FOR A MOVE?) Carnegie Group CGIX (READY FOR A MOVE?) Carnegie Group CGIX (READY FOR A MOVE?) CGII- A company ready to EXPLODE! CGII- A company ready to EXPLODE! CGII- A company ready to EXPLODE!